SCHEMBL88441

SCHEMBL88441

Bc1cccc2ccc3cc4ccccc4cc3c12.CCCN(CCC)CCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.38
ALDH1A1 P00352 1/20 0.38
ERBB2 P04626 1/20 0.37
CYP1A2 P05177 1/20 0.37
FYN P06241 1/20 0.37
MAOA P21397 1/20 0.37
ACHE P22303 1/20 0.37
AHR P35869 1/20 0.37
DRD2 P14416 2/20 0.35
DRD3 P35462 2/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
DRD1 P21728 1/20 0.35
DRD4 P21917 1/20 0.35
DRD5 P21918 1/20 0.35
HTR1B P28222 2/20 0.34
SIGMAR1 Q99720 1/20 0.34
HTR1A P08908 1/20 0.33
HTR6 P50406 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL87634 0.92 HTR1B (0.44) BCHEALDH1A1ERBB2CYP1A2FYN
SCHEMBL88316 0.88 CYP1A2 (0.39) BCHEALDH1A1ERBB2CYP1A2FYN
Trolamine SCHEMBL2028925 0.85 CYP1A2 (0.37) ALDH1A1ERBB2CYP1A2FYNMAOA
Ethylamine SCHEMBL728739 0.84 CYP1A2 (0.41) ALDH1A1ERBB2CYP1A2FYNMAOA
Trimethylammonium SCHEMBL87962 0.84 CYP1A2 (0.43) ALDH1A1ERBB2CYP1A2FYNMAOA
SCHEMBL188027 0.84 CYP1A2 (0.48) ALDH1A1ERBB2CYP1A2FYNMAOA
SCHEMBL298162 0.82 BCHE (0.38) BCHEALDH1A1ERBB2CYP1A2FYN
SCHEMBL10611693 0.82 CYP1A2 (0.47) ALDH1A1ERBB2CYP1A2FYNMAOA
SCHEMBL1109655 0.82 CYP1A2 (0.47) ALDH1A1ERBB2CYP1A2FYNMAOA
SCHEMBL3175604 0.82 CYP1A2 (0.47) ALDH1A1ERBB2CYP1A2FYNMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118284631-A Olefin polymer having excellent processability and process for producing the same 韩华思路信株式会社 2024-07-02 CN claimed
CN-114761448-B Process for producing hybrid catalyst for polymerizing olefin, and olefin polymer 韩华思路信株式会社 2024-04-12 CN claimed
US-20240101728-A1 HYBRID CATALYST COMPOSITION, CATALYST COMPRISING SAME, AND METHOD FOR PREPARING OLEFIN-BASED POLYMER USING SAME Hanwha Solutions Corporation (KR) 2024-03-28 US claimed
US-20240010760-A1 TRANSITION METAL COMPOUND, CATALYST COMPRISING SAME, AND METHOD FOR PREPARING SAME Hanwha Solutions Corporation (KR) 2024-01-11 US claimed
EP-4269453-A1 HYBRID CATALYST COMPOSITION, CATALYST COMPRISING SAME, AND METHOD FOR PREPARING OLEFIN-BASED POLYMER USING SAME Hanwha Solutions Corporation (KR) 2023-11-01 EP claimed
WO-2023191519-A1 TRANSITION METAL COMPOUND FOR OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION CATALYST COMPRISING SAME, AND POLYOLEFIN POLYMERIZED USING SAME 한화솔루션 주식회사 2023-10-05 WO claimed
EP-4253393-A1 TRANSITION METAL COMPOUND, CATALYST COMPRISING SAME, AND METHOD FOR PREPARING SAME Hanwha Solutions Corporation (KR) 2023-10-04 EP claimed
CN-116710495-A Mixed catalyst composition, catalyst comprising the same, and method for preparing olefin-based polymer using the same 韩华思路信株式会社 2023-09-05 CN claimed
WO-2023106779-A1 CATALYST FOR OLEFIN POLYMERIZATION COMPRISING HYBRID CATALYST COMPOSITION AND OLEFINIC POLYMER PREPARED USING SAME 한화솔루션 주식회사 2023-06-15 WO claimed
WO-2023096297-A1 POLYOLEFIN HAVING EXCELLENT PROCESSABILITY AND PROCESS FOR PREPARING SAME 한화솔루션 주식회사 2023-06-01 WO claimed
US-20180201697-A1 CATALYST COMPOSITION INCLUDING NOVEL TRANSITION METAL COMPOUND LG CHEM, LTD. (KR) 2018-07-19 US claimed
EP-3321291-A1 CATALYST COMPOSITION COMPRISING NOVEL TRANSITION METAL COMPOUND LG Chem, Ltd. (KR) 2018-05-16 EP claimed
JP-4705853-B2 2011-06-22 JP claimed
EP-1517928-B1 SUPPORTED HYBRID METALLOCENE CATALYST, METHOD FOR PREPARING THE SAME, AND METHOD FOR PREPARING POLYOLEFIN USING THE SAME LG CHEMICAL LTD (KR) 2010-11-10 EP claimed
US-7294600-B2 Supported hybrid metallocene catalyst, method for preparing the same, and method for preparing polyolefin using the same LG CHEM, LTD. (KR) 2007-11-13 US claimed
EP-1844082-A1 MIXED SUPPORTED METALLOCENE CATALYST, METHOD OF PREPARING THE SAME, METHOD OF PREPARING POLYOLEFIN USING THE MIXED SUPPORTED METALLOCENE CATALYST, AND POLYOLEFIN PREPARED USING THE METHOD OF PREPARING POLYOLEFIN USING THE MIXED SUPPORTED METALLOCENE CATALYST LG Chem, Ltd. (KR) 2007-10-17 EP claimed
US-20060235171-A1 Supported hybrid metallocene catalyst, method for preparing the same, and method for preparing polyolefin using the same LG CHEM, LTD. (KR) 2006-10-19 US claimed
WO-2006080817-A1 MIXED SUPPORTED METALLOCENE CATALYST, METHOD OF PREPARING THE SAME, METHOD OF PREPARING POLYOLEFIN USING THE MIXED SUPPORTED METALLOCENE CATALYST, AND POLYOLEFIN PREPARED USING THE METHOD OF PREPARING POLYOLEFIN USING THE MIXED SUPPORTED METALLOCENE CATALYST LG CHEM, LTD. (KR) 2006-08-03 WO claimed
EP-1517928-A1 SUPPORTED HYBRID METALLOCENE CATALYST, METHOD FOR PREPARING THE SAME, AND METHOD FOR PREPARING POLYOLEFIN USING THE SAME LG Chem, LTD. LG Twin Tower (KR) 2005-03-30 EP claimed
WO-2004087770-A1 SUPPORTED HYBRID METALLOCENE CATALYST, METHOD FOR PREPARING THE SAME, AND METHOD FOR PREPARING POLYOLEFIN USING THE SAME LG CHEM LTD. (KR) 2004-10-14 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180201697-A1 CATALYST COMPOSITION INCLUDING NOVEL TRANSITION METAL COMPOUND COG4, MCM4, ZNF436-AS1 BCHE 3892/4885ALDH1A1 1695/4885ERBB2 1286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.